Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability

American Journal of Surgical Pathology

Volumn 40, Issue 11, 2016, Pages 1496-1506

  Ma, Changqing ^a   Patel, Krishna ^b   Singhi, Aatur D ^a   Ren, Bing ^a   Zhu, Benjamin ^a   Shaikh, Fyza ^b   Sun, Weijing ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

gastric carcinoma with lymphoid stroma; medullary carcinoma; mismatch repair deficiency; signet ring cell carcinoma; tumor microenvironment

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; COMPLICATION; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; STOMACH TUMOR; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; STOMACH NEOPLASMS;

EID: 84979993313     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000698     Document Type: Article

References (38)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence, and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-E386
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697
3. Pardoll DM. the blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-264
4. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4: 127ra137
5. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20: 5064-5074
6. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515: 568-571
7. Llosa NJ, Cruise M, Tam A, et al. the vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015; 5: 43-51
8. Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction, and maintenance of peripheral T-cell tolerance. Blood. 2010; 116: 1291-1298
9. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27: 111-122
10. Fang W, Zhang J, Hong S, et al. EBV-driven LMP1, and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014; 5: 12189-12202
11. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity, and EBV infection induce PD-L1 in Hodgkin lymphomas, and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012; 18: 1611-1618
12. Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression, and immunoresistance in glioma. Nat Med. 2007; 13: 84-88
13. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013; 5: 200ra116
14. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454
15. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515: 563-567
16. Lauwers G, Carneiro F, Graham D, et al. Gastric carcinoma. In: Bosman F, Carneiro F, Hruban R, et al, eds. WHO Classification of Tumours of the Digestive System. Lyon: World Health Organization; 2010: 45-58
17. Chetty R. Gastrointestinal cancers accompanied by a dense lymphoid component: An overview with special reference to gastric, and colonic medullary, and lymphoepithelioma-like carcinomas. J Clin Pathol. 2012; 65: 1062-1065
18. Chiaravalli AM, Feltri M, Bertolini V, et al. Intratumour T cells, their activation status, and survival in gastric carcinomas characterised for microsatellite instability, and Epstein-Barr virus infection. Virchows Arch. 2006; 448: 344-353
19. Saiki Y, Ohtani H, Naito Y, et al. Immunophenotypic characterization of Epstein-Barr virus-Associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes. Lab Invest. 1996; 75: 67-76
20. Kim KJ, Lee KS, Cho HJ, et al. Prognostic implications of tumorinfiltrating FoxP3+ regulatory T cells, and CD8+ cytotoxic T cells in microsatellite-unstable gastric cancers. Hum Pathol. 2014; 45: 285-293
21. Thompson ED, Zahurak M, Murphy A, et al. Patterns of PD-L1 expression, and CD8 T cell infiltration in gastric adenocarcinomas, and associated immune stroma. Gut. 2016; doi: 10.1136/gutjnl-2015-310839
22. Wu C, Zhu Y, Jiang J, et al. Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma, and its clinical significance. Acta Histochem. 2006; 108: 19-24
23. Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4, and Foxp3+ Tregs in gastric cancer, and its clinical significance. Int J Clin Oncol. 2015; 20: 273-281
24. Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells, and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Mol Pathol. 2014; 96: 284-291
25. Tamura T, Ohira M, Tanaka H, et al. Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res. 2015; 35: 5369-5376
26. Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016; 19: 42-52
27. Setia N, Agoston AT, Han HS, et al. A protein, and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016; 29: 772-784
28. Edge S, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. New York, NY: Springer-Verlag New York; 2010: 117-126
29. Tang L, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with carcinoma of the stomach. CAP (Collage of American Pathologists) Cancer Protocols. 2014; Document Number: Stomach 3.3.0.0; http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/2014/Stomach-14Protocol-3300.pdf. Accessed January 13, 2016
30. Washington K. 7th edition of the AJCC Cancer Staging Manual: stomach. Ann Surg Oncol. 2010; 17: 3077-3079
31. Bang Y-J, Chung H-C, Shankaran V, et al. Relationship between PD-L1 expression, and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. ASCO Meeting Abstracts. 2015; 33: 4001
32. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372: 2509-2520
33. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513: 202-209
34. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015; 372: 311-319
35. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-Analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex, and anatomic location. Gastroenterology. 2009; 137: 824-833
36. Lee HS, Choi SI, Lee HK, et al. Distinct clinical features, and outcomes of gastric cancers with microsatellite instability. Mod Pathol. 2002; 15: 632-640
37. Choi YY, Bae JM, An JY, et al. Is microsatellite instability a prognostic marker in gastric cancer?. A systematic review with meta-Analysis. J Surg Oncol. 2014; 110: 129-135
38. Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: An international pooled analysis. Gut. 2014; 63: 236-243